依达拉奉在急性脑梗死治疗中的临床价值研究

Clinical value study of edaravone in the treatment of acute cerebral infarction

目的 分析脑保护剂依达拉奉在急性脑梗死(ACI)治疗中的临床价值,为改善ACI患者的治疗效果提供帮助。方法 选取某院2019年2月—2020年2月收治的ACI患者48例为研究对象,按随机数字表法分为观察组和对照组各24例。对照组采用阿替普酶治疗,观察组采用阿替普酶联合依达拉奉治疗。观察分析两组患者治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力(ADL)评分、出血性转化(HT)发生率、不良反应发生率及临床疗效。结果 两组治疗后NIHSS评分均低于治疗前,且观察组NIHSS评分为(12.35±4.16)分,明显低于对照组的(16.82±4.71)分;两组治疗后ADL评分均高于治疗前,且观察组明显高于对照组;观察组临床治疗总有效率为87.50%,明显高于对照组的62.50%;观察组HT发生率明显低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论 脑保护剂依达拉奉用于治疗ACI可有效改善神经功能障碍,预防HT发生,提高临床疗效,值得临床推广应用。

Objective To analyze the clinical value of brain protective agent edaravone in the treatment of acute cerebral infarction(ACI)and provide help for improving the treatment effect of patients with ACI.Methods A total of 48 patients with ACI admitted to a hospital from February 2019 to February 2020 were selected as the study subjects,and were divided into observation group and control group with 24 cases in each group according to random number table method. The control group was treated with alteplase,while the observation group was treated with alteplase combined with edaravone. The national institutes of health stroke scale(NIHSS)score and the ability of daily living(ADL)score before and after treatment,the incidence of hemorrhagic transformation(HT),the incidence of adverse reactions and the clinical efficacy of the two groups of patients were observed and analyzed. Results The NIHSS scores of the two groups after treatment were lower than those before treatment,and the NIHSS score of the observation group was(12.35±4.16)points,which was significantly lower than that of the control group with(16.82±4.71)points;the ADL score of patients in both groups after treatment was higher than that before treatment,and the observation group was significantly higher than the control group;the total clinical effective rate of the observation group was 87.50%,which was significantly higher than that of the control group with 62.50%;the incidence of HT in the observation group was significantly lower than that in the control group,and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P >0.05). Conclusion Edaravone,a brain protective agent,could effectively improve nerve dysfunction,prevent the occurrence of HT and improve clinical efficacy in the treatment of ACI,which was worthy of clinical promotion and application.